Novo Nordisk (NVO)
(Delayed Data from NYSE)
$135.28 USD
+2.48 (1.87%)
Updated May 31, 2024 04:00 PM ET
After-Market: $135.58 +0.30 (0.22%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$135.28 USD
+2.48 (1.87%)
Updated May 31, 2024 04:00 PM ET
After-Market: $135.58 +0.30 (0.22%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth D Momentum B VGM
Zacks News
Novo Nordisk Inks Diabetes Deal with University of Oxford
by Zacks Equity Research
Novo Nordisk A/S (NVO) and University of Oxford announced a landmark research collaboration for the treatment of type II diabetes.
Novo Nordisk (NVO) Fiasp Gets EU Nod for Diabetes in Adults
by Zacks Equity Research
Novo Nordisk (NVO) announced that its fast-acting insulin aspart, Fiasp, has been approved in the EU for the treatment of diabetes in adults.
Lilly Jardiance Family Diabetes Drugs' Label to be Updated
by Zacks Equity Research
Eli Lilly & Company (LLY) recently announced that the FDA has approved the inclusion of data from the EMPA-REG OUTCOME study on the labels of three type 2 diabetes medicines belonging to the Jardiance family ??? Synjardy, Synjardy XR and Glyxambi.
New Strong Sell Stocks for December 27th
by Indradip Ghosh
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Lilly Stock Surges on Robust 2017 View; Launches Basaglar
by Zacks Equity Research
Eli Lilly and Company (LLY) issued a better-than-expected financial guidance for 2017, alleviating investor concern to a large extent.
Eli Lilly (LLY) to Offer Discount on Insulin from January
by Zacks Equity Research
Eli Lilly (LLY) announced that the company will offer access to its insulin products at discounted prices, starting Jan 2017.
Lilly (LLY) Gets FDA Nod for Once-Daily Version of Synjardy
by Zacks Equity Research
Eli Lilly and Company (LLY) announced the FDA approval of an extended-release formulation of its type II diabetes prescription drug Synjardy.
Should Biotech Investors Worry About Donald Trump?
by Arpita Dutt
It looks like biotech investors may have heaved a sigh of relief a bit too early when Presidential election results were announced last month.
Lilly: Jardiance Label to Add Cardiovascular Indication
by Zacks Equity Research
Eli Lilly & Company (LLY) recently announced that the FDA has approved the inclusion of cardiovascular (CV) risk reduction data from the EMPA-REG OUTCOME study on its type II diabetes drug Jardiance's (SGLT-2 inhibitor) label.
Novo Nordisk Files Regulatory Application for Semaglutide
by Zacks Equity Research
Novo Nordisk (NVO) submitted regulatory application for semaglutide in both the U.S. and the EU for the treatment of adults with type II diabetes.
Novo Nordisk's Tresiba Shows Safe Cardiovascular Profile
by Zacks Equity Research
Novo Nordisk (NVO) announced headline results from the DEVOTE study that confirmed the cardiovascular safety of Tresiba, in comparison to Sanofi???s (SNY) Lantus.
Pharma Industry Stock Outlook - March 2016
by Arpita Dutt
Looking at consensus earnings expectations, the Medical sector, which had performed well in 2015, is expected to see earnings growth of 0.7% and revenue growth of 7.7% in Q1.
Pharma Industry Stock Outlook - March 2016
by Arpita Dutt
Looking at consensus earnings expectations, the Medical sector, which had performed well in 2015, is expected to see earnings growth of 0.7% and revenue growth of 7.7% in Q1.